The goal of this study is o evaluate the prognostic effect of fexofenadine hydrochloride in patients with myocardial infarction
Age ≥ 18 years old.
Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy. He/she or his/her legal representative must provide written informed consent prior to participating in the clinical trial.
Echocardiography indicating segmental wall motion abnormalities.
Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors.
Previous coronary artery bypass grafting (CABG) surgery.
History of severe renal failure with estimated glomerular filtration rate (eGFR) < 30 ml/min.
History of severe liver dysfunction.